3654 results for «370»
3654 results
Personalised Vascular Care Award - Ceremony
20 May 2026 – From EuroPCR 2026
The Personalised Vascular Care Award Ceremony celebrated outstanding achievements in the advancement of personalized vascular treatment approaches, recognizing leaders who have contributed significantly to improving patient outcomes in vascular care.
EuroPCR 2026 Closing Ceremony
22 May 2026 – From EuroPCR 2026
The EuroPCR 2026 Closing Ceremony marks the conclusion of this premier cardiology event, celebrating the latest advances and achievements in interventional cardiology. It offers an opportunity to reflect on the educational sessions, network with peers, and recognize outstanding contributions to the field.
Welcome to EuroPCR 2026
19 May 2026 – From EuroPCR 2026
Welcome to EuroPCR 2026, the premier event for interventional cardiology professionals. This edition offers cutting-edge scientific presentations, live cases, and interactive sessions designed to advance knowledge and clinical practice in cardiovascular interventions.
New frontiers in coronary disease treatment
21 May 2026 – From EuroPCR 2026
Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.
Pharmacology without borders, from coronary artherostenosis to radial artery
21 May 2026 – From EuroPCR 2026
This session delves into the expansive role of pharmacology in interventional cardiology, addressing topics ranging from coronary atherostenosis to radial artery management. Key discussions include the real-world efficacy and safety of intravenous cangrelor-assisted PCI in chronic coronary syndromes, comparative analysis of intra-arterial verapamil versus placebo for...
Focus on heart failure: from acute to chronic
21 May 2026 – From EuroPCR 2026
This comprehensive session delves into the spectrum of heart failure management, from acute presentations to chronic conditions. Key topics include the cardio-hepatic syndrome and right ventricular dysfunction in HFmrEF, prognostic implications of heart failure etiologies, and innovative approaches such as AI-assisted echocardiography for early detection of...
Strategies to enhance bifurcation PCI outcomes
21 May 2026 – From EuroPCR 2026
This session addresses strategies to optimize outcomes in coronary bifurcation PCI. It evaluates the impact of cutting and scoring balloons versus non-compliant balloons on stent expansion, predictors of target vessel revascularization using the POKI technique, and compares stent and non-stent approaches in side branch myocardial infarction...
Aortic stenosis: from diagnostic to treatment
21 May 2026 – From EuroPCR 2026
This session provides an in-depth review of contemporary management of aortic stenosis, covering diagnostic advancements, temporal trends, and treatment outcomes. It includes insights from the LAPLACE-TAVI registry focusing on low-risk patients, discusses the growing feasibility of day-case TAVI procedures, compares transcatheter and surgical valve replacements in...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
PARTNER 3: weighing the comparative costs and savings of TAVI versus SAVR in low-risk patients with severe aortic stenosis
07 Nov 2021
Professor David J. Cohen presented the results of the economic outcomes of the PARTNER 3 trial on Friday, 5 November, in the Late-Breaking Trial session of the Transcatheter Cardiovascular Therapeutics Congress 2021. Giuseppe Biondi-Zoccai provides his analysis of this study.
Author
RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
01 Sep 2024
Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.
The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...
Author
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications
22 Mar 2022
Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.
Author
The 2023 ESH Hypertension Guidelines revisit the role of renal denervation
05 Sep 2023
The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...
Author
Author
Transfemoral TAVI in the horizontal aorta
12 May 2020
Real-world case report illustrating the benefits of the Portico with FlexNav TAVI system.
